A B S T R A C T This report describes a novel method of immunochemotherapy; the active immunization to the drug 5-fluorouracil (5-FU) with enhanced antitumor activity resulting from its subsequent systemic administration. Two metastasizing carcinomas in the Fischer strain (F344) rat have been used: a chemically induced bladder carcinoma (FBCa) and a spontaneous mammary adenocarcinoma (MACa). Both tumors grow rapidly and result in 100% mortality within 10 wk of implantation. Neither tumor is sensitive to systemic 5-FU alone. Intradermal sensitization to 5-FU before FBCa tumor implantation, followed by 5-FU administered systemically, resulted in significant tumor regression and improvement in survival with eradication of all tumor and cure in 20% of animals. A similar antitumor effect was observed with the MACa. A comparable drug effect was observed when methotrexate sensitization was given before FBCa implantation followed by systemic MTX. Specificity to the sensitizing drug was demonstrated by the lack of effect of sensitization with either 5-FU or MTX unless followed by systemic therapy with the requisite sensitizing agent. Sensitization to 5-FU has also been assessed after FBCa implantation followed by resection of the local tumor. Resection was performed after distant tumor metastases had occurred, and was followed by systemic 5-FU therapy. Whereas tumor resection alone failed to cure any animal, sensitization to 5-FU increased cure rate fourfold over animals receiving sys- 558 temic 5-FU alone. Antibody to 5-FU in the sera of sensitized animals has been suggested by an immunoenzymatic staining technique and its specificity confirmed in a radioimmunoassay. It is postulated that a combination of the systemic agent and the antibody elicited to it by sensitization produces the significant antitumor effect observed. The antitumor effect observed with this new approach to immunochemotherapy warrants further experimental and clinical study.
A B S T R A C T This report describes a novel method of immunochemotherapy; the active immunization to the drug 5-fluorouracil (5-FU) with enhanced antitumor activity resulting from its subsequent systemic administration. Two metastasizing carcinomas in the Fischer strain (F344) rat have been used: a chemically induced bladder carcinoma (FBCa) and a spontaneous mammary adenocarcinoma (MACa). Both tumors grow rapidly and result in 100% mortality within 10 wk of implantation. Neither tumor is sensitive to systemic 5-FU alone. Intradermal sensitization to 5-FU before FBCa tumor implantation, followed by 5-FU administered systemically, resulted in significant tumor regression and improvement in survival with eradication of all tumor and cure in 20% of animals. A similar antitumor effect was observed with the MACa. A comparable drug effect was observed when methotrexate sensitization was given before FBCa implantation followed by systemic MTX. Specificity to the sensitizing drug was demonstrated by the lack of effect of sensitization with either 5-FU or MTX unless followed by systemic therapy with the requisite sensitizing agent. Sensitization to 5-FU has also been assessed after FBCa implantation followed by resection of the local tumor. Resection was performed after distant tumor metastases had occurred, and was followed by systemic 5-FU therapy. Whereas tumor resection alone failed to cure any animal, sensitization to 5-FU increased cure rate fourfold over animals receiving sys- INTRODUCTION 5-Fluorouracil (5-FU)' was synthesized in 1957 (1) , and since then has become an established antineoplastic agent used clinically in the treatment of various human solid tumors (2) (3) (4) (5) (6) . The biochemical mechanisms of action for 5-FU have been studied extensively (7) (8) (9) with particular emphasis on thymidylate synthetase inhibition (10) and incorporation of 5-FU into RNA (11) . Metabolic modulation to enhance either of these two actions has failed to show a causal link with therapeutic efficacy (11) (12) (13) and the relative importance of each remains controversial. Neither mechanism excludes an antitumor effect separate from these antimetabolic actions.
The concept that 5-FU acts primarily as a cytotoxic drug affecting rapidly dividing cells has lead to the use of high doses that are active against not only tumor cells, but also cells of the gastrointestinal mucosa and the hematopoietic system (14, 15) . It has been assumed that 5 -FU is immunosuppressive because of the inhibitory effects seen at these high doses (15) . Studies of the effect of 5-FU and other fluorodinated pyrimidines on the rodent immune response have been conflicting (16) . Merrit (20) . The disparate effects of 5-FU on rodent immune responses can be attributed to differences in dosage and in timing of administration in relation to antigen stimulation. These factors are often of critical importance in the immune response to any agent.
It is therefore conceivable that, with particular dosage and timing, 5-FU could augment antitumor responses. We had noted that in some patients with accidental extravasation of 5-FU, an Arthus reaction occurred at that site upon further administration of 5-FU at a separate intravenous site. This suggested that an immunoglobulin G (IgG)-mediated immune response to 5-FU had developed in these patients. In certain of the above patients who received lower doses of 5-FU because of toxicity at conventional doses, therapeutic efficacy of chemotherapy appeared increased. In fact, it was observed in two of these cases that at subsequent autopsy they were histologically tumor free, despite diffuse intraabdominal metastases of the tumor at earlier surgery. These incidental clinical observations raised the possibility that the efficacy of 5-FU was not dependent only on the cytotoxic effect on tumor cells.
An experimental model was designed to elucidate the basis of these clinical observations. Rats were treated with various low doses of intradermal 5-FU before and after tumor implantation, after which moderate doses of the same drug were administered systemically. This design was meant to test the possibility that immunologic sensitization to the drug could be achieved by low dose intradermal injection, resulting in a subsequent altered systemic effect.
This report describes: (a) the requirements for immunological sensitization to the drug, (b) the markedly increased antitumor effect of 5-FU on two metastasizing rat tumors seen after sensitization, (c) the ability of methotrexate (MTX) to produce a similar effect, (d) the drug specificity of the sensitization produced, and (e) evidence by two techniques that circulating antibody to the drug is present in the sera of the sensitized animals. METHODS Chemicals. 5 ,g/ml. Target cells were then applied to microscope slides by air drying and ethanol/ether mixture fixation. Sera to be tested were applied to the target cells for 10-120 min. The slides were then rinsed twice in PBS for 15 min and stained with peroxidase-conjugated rabbit anti-rat IgG. Both rat and peroxidase-labeled sera were absorbed before use with murine liver powder and lymphocytes. The sites of specific binding of the peroxidase-conjugated antibody were then demonstrated using Karnovsky's solution (23) . Radioimmunoassay for the detection of anti-5-FU antibodies was performed using nitrocellulose filters as described by Gershman et al. (24) and Schreiber and Raso (25) . Briefly 0.25-10 M1 of sera from control and 5-FU presensitized animals diluted to 400 ,ul with Tris buffer (0.01 M, pH 7.4, 0.14 M NaCl) were incubated with 10 !sl of [14C]-5-FU (400 Ag/ ml specific activity 482 ,uCi/mg) for 60 min at 22°C. Unbound radiolabeled drug was separated by passage through a nitrocellulose filter membrane (GS, 0.22 ,um) using the multiple filtration manifold (Millipore Corp., Bedford, MA). Filters were washed with 10 ml of Tris buffer, dried, and the radioactivity of the bound material measured in a scintillation counter.
Statistics. Tumor growth was analyzed using the unpaired Student's t test. Analyses of variance of the animal response was also done. Comparison among the means across time as well as across treatment was assessed using Duncan's multiple range test for variable responses. Mortality and percentage of regression were compared using Chi-square analysis with Yates correction factor. A P value of <0.05 was considered significant in all tests.
RESULTS
Assessment of low doses of 5-FU on tumor growth. The effect of low dose pretreatment with intradermal 5-FU on local tumor growth and the incidence of metastases of FBCa was studied. Male (F344) rats (n = 60) were divided into three experimental and five control groups. Animals were pretreated with either one dose at 14 d (n = 5) (Fig. 1, group 1) , two doses at 28 and 14 d (n = 5) (Fig. 1, group 2) or with three doses at 42, 28, and 14 d (n = 5) before receiving tumor ( Fig. 1, group 3) . The pretreatment dose in these experiments consisted of 5-FU 0.1 mg/kg body wt injected intradermally in the dorsal aspect of the animals. No local cutaneous reactions were observed at the injection site. All three groups then received weekly systemic treatment with 5-FU (10 mg/kg, i.v.) beginning at 7 d after tumor implantation.
The control groups for the above experiment received either no treatment (n = 15) (Fig. 1, group 4) , systemic therapy alone (n = 15) (Fig. 1, group 5 ), or pretreatment with 1 (n = 5), 2 (n = 5), or 3 (n = 5) doses as for the experimental groups but without systemic therapy (Fig. 1, groups 6-8 ). There was no significant difference in tumor behavior between the control groups. The tumor growth (Fig. 2 ) was identical and survival was 20% by 60 d and 9% by 70 d post FBCa implantation (Table I) , and 80% of animals dying were found to have pulmonary metastases at autopsy. Neither systemic treatment nor pretreatment with intradermal 5-FU was sufficient in itself to produce an antitumor effect. Fig. 2 depicts the growth curves of FBCa for those rats receiving low dose pretreatment and subsequent systemic treatment (Fig. 1,  groups 1-3) . Pretreatment with one dose of 5-FU, with subsequent systemic treatment demonstrated no difference in the antitumor response compared with the controls. The presensitization treatment effect manifested at two doses before tumor implantation and the decreased rate of tumor growth was highly significant when three doses were used to presensitize animals followed by systemic therapy ( Fig. 2A, animals in this group were surviving at 10 wk compared with none in the control (Table I, A) .
The results observed for three pretreatment doses plus systemic therapy were then confirmed in a second experiment with increased numbers (Fig. 2B , n = 20/ group). The tumor growth in control and presensitized animals was compared by analysis of variance and again the three-dose presensitization schedule was highly effective in retarding tumor growth (P = 0.0001 using Duncan's multiple range test-see legend Fig.  2B ). Moreover, 20% of these animals (n = 5) demonstrated marked regression with complete disappearance of the tumor. At 10 wk, systemic administration of 5-FU was stopped. 30 wk after tumor implantation these five animals remained free of recurrence and, when sacrificed, showed no metastases.
Evaluation of the antitumor effect of pretreatment on a rat mammary adenocarcinoma. An identical protocol (Fig. 1 ) but using MACa was used in female F344 rats to determine whether the antitumor effect observed with FBCa was applicable to other tumor models. As seen in Fig. 3 , the growth of MACa in the experimental group (n = 10) receiving three pretreatment doses of 5-FU (0.1 mg/kg, i.d.) at 42, 28, 14 d before MACa implantation, with subsequent weekly administration of systemic therapy (10 mg/kg, i.v.) beginning 7 d after tumor implantation was compared with controls receiving either no treatment (n = 10), systemic therapy alone (n = 10), or three pretreatment doses without systemic therapy (n = 10).
No difference in tumor growth was observed among the control groups; no control animals survived 10 wk and 60% of those dying were demonstrated to have pulmonary metastases. Experimental animals demonstrated a significant inhibition of tumor growth (P < 0.05) (Fig. 4) . Complete regres&ion without recurrence was seen in 20% (n = 2) of experimental animals and 10-wk survival was 80% (n = 8), (P < 0.01) (Table  IB) . No metastases were found in any of the experimental animals at death.
Evaluating the effect of varying the dosage and timing of pretreatment on antitumor effect. To determine the optimum dose of 5-FU for intradermal pretreatment and schedule of administration necessary for maximum antitumor effect, the following experiment was performed. Experimental groups (n = 5) were given either three pretreatment doses of (a) 0.05, 
wk) afterwards (-). The volumes (mean±SE)
were compared with those of rats receiving no treatment (0) and systemic therapy alone (0) (n = 10 for each group) (°P < 0.05, a a P < 0.001).
drug vehicle (saline) intradermally. The systemic treatment, 10 mg/kg, i.v. weekly from day 7 after FBCa implantation, was kept the same as described in sections 1 and 2.
Control animals received either no treatment (n = 5), systemic therapy alone (n = 5), or pretreatment as for (a)-(c) above (n = 5/group) but without systemic therapy. There was no significant difference between the controls receiving no treatment, only systemic therapy, or only pretreatment. The tumors grew as previously, (Fig. 2, controls) with no survival past 10 wk and 90% incidence of pulmonary metastases detectable at autopsy.
Tumor growth was initially inhibited for 2-4 wk in all experimental animals that received both pretreatment and subsequent systemic therapy (P < 0.05). However, in all groups except (a) and (b), tumor volume returned to that of controls by 42 d after implantation and no significant difference was observed in survival or occurrence of metastases. A comparison of the degree of regression observed can be seen in Fig. 4 . Three pretreatment doses of 0.05 mg/kg (group a) produced a greater and more prolonged regression with 60% 10-wk survival (P < 0.01). However, no complete regression was observed.
The maximum antitumor effect was observed using 0.1 mg/kg for three doses on 42, 28, and 14 d before implantation and was the basis for the protocol selected for both FBCa and MACa in the above experiments (Fig. 1, group 3) . Tumor regression was greater and lasted longer in this group (P < 0.05). There was 80% survival at 10 wk (P < 0.01) and 40% (n = 2) complete regression.
The effect of intradermal 5-FU after tumor implantation but before systemic administration. To assess the effect of intradermal treatment on existing tumor, experimental animals (n = 10) received intra- dermal 5-FU (0.1 mg/kg) at 3, 10, and I implantation ( Fig. 1 group 9 ). Subsequ4 temic therapy (10 mg/kg, i.v.) was ad ginning 28 d after tumor implantatioi ceived either no treatment (n = 10), or apy alone (n = 10) ( Fig. 1 groups 10 -12) was observed between these contro growth and mortality were comparal experiments. In the experimental grou regression was observed. However, tun significantly retarded (P < 0.05) (Fig. wk survival was 70% (P < 0.01) (Tabl The effect of intradermal 5-FU spread following resection of the locc demonstration that intradermal 5-Ft under the experimental conditions outl duced tumor growth, and prolonged s mals with neoplastic disease, led to an assess its effect on the development of r design of this experiment was as descri 4 with the addition of a surgical resect tumor at 21 d after FBCa implantatior 13). The control groups for this exper: sected similarly and were treated as oi 5 ( Fig. 1 groups 14-16 mals sensitized to MTX before tumor implantation were given systemic 5-FU (10 mg/kg, i.v. weekly) (n = 5).
There was no significant difference in tumor behavior between any of the control groups, which was the same as described earlier. Neither 5-FU nor MTX systemic therapy alone produced any effect on local tumor growth, survival, or incidence of metastases. 5-FU sensitization followed by 5-FU systemic therapy produced marked tumor regression (P = 0.0058 using Duncan's multiple range test) (Fig. 6) and 60% survival at 10 wk (P < 0.01) (Table III) reconfirming the previous results. MTX pretreatment produced a similar antitumor effect when systemic MTX was subsequently administered. Again, marked tumor regression was observed (Fig. 6 ) (P = 0.0027 comparing means across time using Duncan's multiple range test for variable responses) and survival at 10 wk was 80% (P < 0.01) with one animal showing complete regression and cure of tumor (Table III) .
The drug specificity of the pretreatment effect described above was confirmed by the finding that MTX sensitization followed by systemic therapy with 5-FU The number of FBCa-bearing rats surviving at 10 wk and the number of rats cured of FBCa from the experiment described in failed to produce any effect on tumor growth or animal survival ( Fig. 6 , P = 0.2979) ( Table III) . Assessment of antibody to 5-FU in sera of pretreated animals. Experimental and control sera were tested at least five times by the indirect immunoenzyme staining assay. The experimental sera from rats pretreated with three doses of 5 (Fig. 7) . The specificity of the binding was tested using sera from animals pretreated with MTX. These sera showed no increase in binding to 5-FU compared with background levels determined when normal rat serum was used in the assay.
DISCUSSION
It has been demonstrated, in two rapidly growing tumors, FBCa (27) . This complex may be the basis of the mechanism by which the observed increased in antitumor effect by presensitization occurs.
It is theoretically possible that the observed antitumor effect with low dose sensitization is purely antimetabolic, and therefore not immunologic or drug specific. This is particularly expected as MTX and 5-FU can act synergistically to interfere with the same biochemical step in DNA synthesis (28) . If this were so it would be expected that MTX sensitization could also affect the efficacy of subsequent 5-FU systemic therapy. However, no such enhancement occurred. The apparent drug specificity is further supportive of an immune mechanism.
Although clinical hypersensitivity has been described against many chemotherapeutic agents (5, 13, 29), it has not as yet been reported with 5-FU. As well, most observers of this drug sensitivity have viewed the phenomenon from the standpoint of toxicity such as the production of anaphylaxis or circulating immune complex-mediated disease. Our studies suggest that the development of sensitivity by active immunization to a drug may in fact be beneficial. Although hypersensitivity has not been reported with 5-FU, the physicochemical properties of 5-FU have the prerequisites for haptenic activity (cf. other small molecules such as dinitrophenol). Furthermore, antibody formation has been described to nonfluorodinated pyrimidines, including uracil (30, 31) .
The presence of an antibody to 5-FU in the sera of 5-FU sensitized animals has been demonstrated by radioimmunoassay and immunoenzymatic localization techniques. The binding to the radiolabeled drug was specific to the sensitizing drug. Furthermore, the presence of this anti-5-FU binding activity correlated with the effectiveness of subsequent systemic 5-FU therapy on both local and metastatic tumor growth. The mechanism by which antibody formed against a cytotoxic drug increases tumor cell destruction by that drug remains hypothetical. The therapeutic value of cytotoxic drugs coupled to specific antibody has been studied extensively in the form of passive immunization (32, 33) . Administration of drugs chemically linked in vitro to heterogeneous antitumor immunoglobulin may act by increasing target selectivity, with antibody identifying the tumor cell and directing the drug against it. It is also suggested in the literature that the antibody can facilitate the entry of the drug into the tumor cell by altering the tumor cell membrane. The antibody directed against the cytotoxic drug could have a similar mechanism of action on the cell surface as passively administered antibody.
Another possible mechanism of action of antidrug antibody complexes on any cell surface is that this bound complex may cause binding of Fc receptor bearing cells to the Fc portion of the antibody. Macrophages and neutrophils have such Fc receptors, and both are found in substantial numbers in solid tumors. The binding of these phagocytic cells could then lead to tumor destruction. In addition to binding to Fc receptor, the drug-antibody complex(es) could be phagocytosed by and thus activate macrophages with resultant tumor cell destruction.
A novel method of immunochemotherapy with minimal toxicity has been described. Although the exact mechanism of action remains to be defined, the dramatic antitumor responses observed deserve further experimental and clinical investigation.
